Trails Edge Capital Partners LP Makes New Investment in Xenon Pharmaceuticals Inc. $XENE

Posted by Francis Steltz on Aug 26th, 2026

Trails Edge Capital Partners LP acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 440,000 shares of the biopharmaceutical company’s stock, valued at approximately $26,558,400,000. Xenon Pharmaceuticals comprises about 4.2% of Trails Edge Capital Partners LP’s investment portfolio, making the stock its 8th biggest position. Trails Edge Capital Partners LP owned about 0.46% of Xenon Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in XENE. Goldman Sachs Group Inc. lifted its position in Xenon Pharmaceuticals by 7.9% during the first quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after buying an additional 32,486 shares during the period. Jump Financial LLC acquired a new position in shares of Xenon Pharmaceuticals during the 2nd quarter valued at about $532,000. Sei Investments Co. purchased a new position in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $711,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Xenon Pharmaceuticals in the second quarter worth approximately $816,000. Finally, Alliancebernstein L.P. grew its holdings in Xenon Pharmaceuticals by 14.2% in the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after purchasing an additional 189,141 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on XENE shares. Royal Bank Of Canada cut their price target on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $74.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, August 10th. JPMorgan Chase & Co. upped their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Finally, Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $77.13.

Check Out Our Latest Stock Report on Xenon Pharmaceuticals

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the sale, the director directly owned 1,870 shares in the company, valued at $119,792.20. The trade was a 84.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,512 shares of company stock worth $774,088 in the last 90 days. 2.91% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock opened at $60.42 on Wednesday. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66. The firm has a market capitalization of $5.84 billion, a P/E ratio of -12.75 and a beta of 0.62. The company’s fifty day moving average price is $62.65 and its two-hundred day moving average price is $56.05.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period last year, the company earned ($1.07) EPS. On average, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current year.

Xenon Pharmaceuticals Company Profile

(Free Report)

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.